GS US 454 4378: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of IP in Subjects with Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH)

March 09, 2018
https://clinicaltrials.gov/ct2/show/NCT03449446
Gastroenterology Hepatology
Principal Investigator: Kimberly A Brown, MD
liver, fatty, NASH, nonalcoholic, steatohepatitis, hepatology, gastroenterology
Accepting Participants